Compare · BSX vs SIBN
BSX vs SIBN
Side-by-side comparison of Boston Scientific Corporation (BSX) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 82.5x SIBN ($875.8M).
- SIBN has been more active in the news (14 items in the past 4 weeks vs 10 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 12 for SIBN).
- Company
- Boston Scientific Corporation
- SI-BONE Inc.
- Price
- -
- -
- Market cap
- $72.26B
- $875.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 10
- 14
- Recent ratings
- 25
- 12
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
Latest SIBN
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $1,088,201 worth of shares (55,807 units at $19.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Op & Financial Officer Maheshwari Anshul sold $337,138 worth of shares (16,975 units at $19.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 234,920 units (SEC Form 4)
- SEC Form 144 filed by SI-BONE Inc.
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $279,065 worth of shares (14,956 units at $18.66), decreasing direct ownership by 2% to 493,900 units (SEC Form 4) (tax liability)
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $69,411 worth of shares (3,725 units at $18.63), decreasing direct ownership by 1% to 273,650 units (SEC Form 4) (tax liability)
- Chief Financial Officer Maheshwari Anshul sold $87,016 worth of shares (4,665 units at $18.65), decreasing direct ownership by 2% to 251,895 units (SEC Form 4) to cover withholding tax
- SEC Form SCHEDULE 13G filed by SI-BONE Inc.
- Director Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $369,214 worth of shares (20,000 units at $18.46) as part of a pre-agreed trading plan (SEC Form 4)